Drug Type saRNAs |
Synonyms MTL CEBPA |
Target |
Mechanism CEBPA stimulants(CCAAT enhancer binding protein alpha stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Hepatocellular Carcinoma | Phase 2 | US | 01 Jan 2022 | |
Advanced Hepatocellular Carcinoma | Phase 2 | SG | 01 Jan 2022 | |
Hepatitis B | Phase 2 | US | 01 Jan 2022 | |
Hepatitis B | Phase 2 | SG | 01 Jan 2022 | |
Hepatitis C | Phase 2 | SG | 01 Jan 2022 | |
Hepatitis C | Phase 2 | US | 01 Jan 2022 | |
Hepatocellular Carcinoma | Phase 1 | TW | 01 Mar 2016 | |
Liver Cancer | Phase 1 | - | - | |
Liver Cancer | Phase 1 | - | - | |
Liver Cancer | Phase 1 | - | - |
Phase 1 | 50 | pembrolizumab+MTL-CEBPA (dose escalation) | (guvqlbojhf) = rhsvanaigc wnzdyhqeyh (rkpgxqyagq ) View more | Positive | 12 Nov 2022 | ||
pembrolizumab+MTL-CEBPA (dose expansion) | (guvqlbojhf) = vwirknawcc wnzdyhqeyh (rkpgxqyagq ) View more | ||||||
NCT04105335 (SITC2021) Manual | Phase 1 | 10 | MTL-CEBPA+pembrolizumab | (emynoyreat) = 2AEs in 1 pt only were grade 3 (ALT and AST increases) zritoypuiy (pblzbvnkwq ) View more | Positive | 11 Nov 2021 | |
Phase 1 | 38 | (juihyvlhus) = jxjkvtulzh fhrnapkrof (eyoelkxwfl ) View more | Positive | 01 Aug 2020 | |||
Phase 1 | 19 | (uibxathwzt) = one patient having an ongoing PR for 18 months associated with 73% decrease in tumour volume and reduction in IL-6, NF-κB and IFN-γ iqjuhdclvq (wmwszgqhtg ) View more | Positive | 01 Jun 2018 |